Resolves Yes if the FDA grants full or accelerated approval to a drug with a claimed disease-modifying mechanism of action for Alzheimer's disease, with an approval date in 2026 and distinct from previously approved agents (lecanemab, donanemab). Resolves No otherwise.
FDA drug approvals database (fda.gov/drugs/nda-and-bla-approvals)
Outcome is assigned to exactly one published option, then reputation is updated.
The question, options, source, cutoff, and resolution criteria are visible before voting.
Verified humans submit one encrypted answer. Counts remain hidden until cutoff.
The resolver checks the named source-of-truth against the locked criteria.
Receipt lookup, resolution evidence, and topic reputation become publicly reviewable.
After cutoff, CivicSignal keeps the vote set sealed until resolution. When the named source answers the question, the outcome, resolver notes, and audit trail appear on the public resolution record.